To directly evaluate the necessity of the STING pathway activation in tumor cells for P2‐induced immune cell recruitment in vivo, we used CRISPR/Cas9 to deplete STING in MC38 cells and subcutaneously injected these tumor cells into syngeneic mice. This evidence concerns the gene STING1 and neoplasm.